Genmab — November 2020

[GeorgeBest]

Nordea siger Tepezza royalty procentsats er 6,5%

[E_L]

DnB Markets
Rune Majlund Dahl

Genmab

• Good Q3 growth in key products
  In their Q3 reports, JnJ and Horizon noted higher Darzalex and Tepezza sales, respectively, than we and consensus expected. We have updated our Q3e sales accordingly, and are now c14% above consensus, supporting our view that the 2020 guidance should be narrowed towards the high end. We reiterate our HOLD and DKK2,352 target price.

[Sukkeralf]

Så er Novod ved at være on par med kursen - dejligt trods alt

[E_L]

Halozyme Therapeutics Inc (HALO) Q3 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/11/02/halozyme-therapeutics-inc-halo-q3-2020-earnings-ca/

[Sukkeralf]

No royalty mentioned ?

[E_L]

no

[E_L]

Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q3 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4384100-horizon-therapeutics-plc-hznp-ceo-timothy-walbert-on-q3-2020-results-earnings-call-transcript?part=single

[E_L]

ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors https://ir.adctherapeutics.com/press-releases/press-release-details/2020/ADC-Therapeutics-Announces-First-Patient-Dosed-with-Camidanlumab-Tesirine-Cami-in-Combination-with-Pembrolizumab-in-Ongoing-Phase-1b-Clinical-Trial-in-Selected-Solid-Tumors/default.aspx

[Solsen]

Det kan potentielt være en trussel imod GEN1046. Men interessant.

[Bulder]

Hvis Cami kan kombineres med pembro, kan den vel også kombineres med gen1046?

[Sukkeralf]

Jo men konkurrencen her er jo enorm - der er vel intet felt der er større end kombinationer med checkpoint inhibitorer.

[Solsen]

Camis virkemekanisme er som jeg forstår, det vi troede Dara gjorde i solide, hvi

[Solsen]

hvis I husker det

[Sukkeralf]

Ja CD25 positive Tregs bliver smadret - og for Dara CD38 positive Tregs.

[E_L]

I actually saw earlier today Merus had 2 Late Breaker posters at SITC as competitor to GEN1046 "MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity."

[E_L]

they will be working out of the same building soon in Utrecht, they can fight it out in the lobby lol

[Bulder]

that's more a direct competitor as cd137 is the same as 4-1BB

[E_L]

exactly

[E_L]

this is what i was looking for, in the Utrecht Science park https://www.utrechtsciencepark.nl/en/home/about-the-park/news/genmab-and-merus-are-cooperating-with-kadans-science-partner-as-developer-for-the-accelerator-on-utrecht-science-park

[E_L]

this was their poster last year at aacr,
very similar, also in the clinic now https://ir.merus.nl/static-files/4697ce0b-6b48-4e8e-8a69-a435e414a0a6